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Abstract
The rates of recurrent venous thromboembolism (RVTE) vary widely, and its causes still need to be elucidated. Statistical
multivariate methods can be used to determine disease predictors and improve current methods for risk calculation. The
objective of this study was to apply principal component analysis to a set of data containing clinical records of patients with
previous venous thromboembolism and extract the main factors that predict recurrent thrombosis. Records of 39 factors
including blood and lipid parameters, hereditary thrombophilia, antiphospholipid syndrome, clinical data regarding previous
thrombosis and treatment, and Doppler ultrasound results were collected from 235 patients. The results showed that 13 principal
components were associated with RVTE and that 18 of 39 factors are the important for the analysis. These factors include red
blood cell, white blood cell, hematocrit, red cell distribution width, glucose, lipids, natural anticoagulant, creatinine, age, as well as
first deep vein thrombosis data (distal/proximal, D-dimer, and time of anticoagulation). The results demonstrated that simple
clinical parameters easy to be collected can be used to predict rates of recurrence and to develop new clinical decision support
systems to predict the rates of RVTE.
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Introduction
Recurrent venous thromboembolism (RVTE) is an important
subject in any medical center. Once the patient is diagnosed
with a first venous thromboembolism (VTE), anticoagulation
therapy is the prevention method of recurrence commonly
used. However, the duration of anticoagulation therapy is a
difficult decision and depends on multiple factors that interact
with each other and need to be evaluated individually.1-5 Dash,6
Vienna,7 and Men and HERDOO-28 are 3 scores used to decide
about anticoagulant prophylaxis by the risk of recurrence, and
each one takes different factors in consideration.
Recent reviews showed that these score models have a
strong limitation when predicting patients with low risk of
RVTE and still lacks a complete validation.9,10 Patients with
provoked VTE are also not included in these models. There are
some studies indicating that some patients with provoked VTE
could benefit of prolonged prophylaxis11-13 and also that they
have the same risk of recurrence when comparing those with a
previous unprovoked event.14 The scores also does not include
patients with antiphospholipid antibody syndrome, cancer, nat-
ural anticoagulant activity deficiencies, and so on.9,10
Thus, it is important for the development of prediction
scores that include those individuals. To overcome these issues,
sophisticated multivariate statistical techniques could be used
to identify the main risk factors of RVTE for a wide range of
patients.
Principal component analysis (PCA) is a multivariate statis-
tical method that identifies patterns and classifies the factors
that influences a given phenomenon. It is a technique widely
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Paulo, Brazil
3 Hematology and Hemotherapy Center, University of Campinas/
Hemocentro-Unicamp, Instituto Nacional de Ciência e Tecnologia do Sangue,
Campinas, São Paulo, Brazil
Corresponding Author:
Tiago D. Martins, Departamento de Engenharia Quı́mica, Universidade Federal
de São Paulo, Instituto de Ciências Ambientais, Quı́micas e Farmacêuticas, Rua
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used to identify patterns in the medical field.15-19 Principal
component analysis is a decomposition of a set of correlated
variables into a set of uncorrelated variables, named as princi-
pal components (PCs), which are organized by descending
order of variance. Principal component analysis can also be
used to reduce dimensionality by cutting the PCs that are less
important (less variance) than the original data. The remaining
PCs are useful to develop new models, and their loadings can
be used to calculate the contribution of each factor in the col-
lected data.
The aim of this study was to collect clinical data of several
patients diagnosed with a first thrombotic episode and use PCA
to identify the predictor factors for RVTE. To obtain a more
comprehensive view of the risk factors, we included patients
with provoked and unprovoked VTE, antiphospholipid anti-




In this study, 261 consecutive patients with a first acquired or
provoked VTE, assisted at outpatient clinic of Hemocentro
Unicamp between January 2009 and August 2016, were fol-
lowed. Mathematically, the occurrence of RVTE (or not) can
be considered as a function of several risk factors. Acquired
risk factors for VTE were pregnancy and postpartum, hormone
therapy for contraception or hormonal replacement, surgery,
trauma, air travel, hereditary thrombophilia, cancer, and anti-
phospholipid antibodies. Exclusion criteria were patients with
missing data, thrombosis that occurred in other sites than pul-
monary embolism (PE), lower limbs or central nervous system,
and age under 18 years. After the first VTE, all patients were
treated with anticoagulant therapy during the standard 6-month
period. Then, every 6 months, each patient returns to the clin-
ical center for check-up examinations.
Recurrent VTE was defined by the detection of a novel
thrombotic episode at a different site from the primary event
or a new episode occurred at the same localization of previous
thrombosis. Thrombosis of the limbs was confirmed by duplex
ultrasonography, thrombosis of the cerebral veins by magnetic
resonance imaging, and PE by ventilation-perfusion scanning
or magnetic resonance imaging.
Table 1 shows all the evaluated factors, which included
clinical, thrombotic data, acquired and inherited risk factors
for thrombosis, laboratorial parameters, and residual vein
thrombosis detected by ultrasound Doppler. All patient data,
blood samples, and examinations were collected between the
first and the second thrombotic events in an average time of 1
month after the end of anticoagulation therapy. The 39 factors
presented in Table 1 were used to perform the PCA. Since there
are some factors that are not numerical data, they were con-
verted to a numerical form as shown in Table 2. All numerical
factors were used as is.
Principal Component Analysis
The PCs are a new set of variables that are organized in order of
its capacity to describe a given phenomenon. To calculate the
PCs from an original data matrix X, it is necessary to eliminate
data heterogeneity. This can be done by centering the mean in
zero and the variance in 1, for each variable from X. Equation 1
is used for this purpose:
Zi;j ¼ s1=2j ðXi;j  mjÞ; i ¼ 1; n; j ¼ i;m; ð1Þ
where Xi, j is the ith observation of variable j, Zi, j is the stan-
dardized variable of Xi, j, and mj and sj are the mean value and
the variance of the variable j, respectively. Both n and m are the
total number of observations and variables, respectively.
Table 1. Factors Considered in the Present Study.
Sex (men/women) G20210A prothrombin gene
mutation (No/Yes)
Red blood cell (RBC)
count, mL1
Fasting blood glucose, mgdL1
Age, years Factor VIII (IUdL1) Hemoglobin (HB) (gdL1) Creatinine (mgdL1)
Pulmonary embolism
(No/Yes)
Protein C level (PC) (mg dL-1) Hematocrit (HCT) (%) C-reactive protein (mgdL1)
Side of inferior member (left/
right)
Protein S level (PS) (mg dL-1) Red blood cell distribution
(RDW) (%)
Arterial hypertension (No/Yes)
Location of VTE in leg (distal/
proximal)
Antithrombin level (AT) (mg dL-1) Platelet (PLT) (mL-1) Diabetes mellitus (No/Yes)
Provoked or unprovoked Antiphospholipid syndrome (No/
Yes)
Mean platelet volume (MVP)
(fL)
Dyslipidemia (No/Yes)
Anticoagulation time, months Body mass index (BMI) Total cholesterol (mgdL1) Renal failure (No/Yes)
Anticoagulant use (No/Yes) Smoking (No/Yes) High-density lipoprotein (HDL)
(mgdL1)
Cancer (No/Yes)




Residual venous thrombus on US
Doppler (No/Yes)
FV Leiden (No/Yes) White blood cell (WBC)
count (mL1)
Triglycerides (mgdL1)
Abbreviations: FV, factor V; US, ultrasound; AT, Antithrombin; PS, Protein S.
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Once the matrix Z is obtained, the variance–covariance
matrix can be obtained. The PCs can be generated by calculat-
ing the eigenvector and the eigenvalues for the matrix Z and are




akjZj; k ¼ 1;m: ð2Þ
The importance of each PC can be determined by ordering
the eigenvalues in a descending order, corresponding to the
descending order of variance.
In this study, PCA was used to determine the main factors
for RVTE. We considered only the PCs in which eigenvalue is
greater than 1, which assures that the set of PCs are more
important than the original variables. To compute the impor-
tance of each factor Zj in a PCk, the correlation, rZjPCk , was





; j; k ¼ 1; 2; . . . ;m; ð3Þ
where ajk is eigenvector value of the jth stardardized variable Z
with respect to the kth PCs, and lj is the eigenvalue of the jth
stardardized variable Z.
Only those variables with jrZjPCk j > 0:5 were considered as
important factor.
Results
From all 261 patients, 26 were excluded because they presented
missing data, a first VTE in other sites than pulmonary, lower
limbs or central nervous system, and age under 18 years. There-
fore, 235 patients were included whereas 74 (31.4%) were men
and 161 were women, age >18 and <82 years.
Table 3 summarizes the principal characteristics of the
thrombotic episodes. In all, 49 (20.8%) patients presented
recurrent VTE. The first episode was more predominant in the
left leg (45.7%); 36% of the patients presented pulmonary
embolism (PE), and only 2.1% presented thrombosis in the
central nervous system. When analyzing RVTE events, the
percentages were almost the same: 46.0%, 30.0%, and 2.0%
for patients who presented RVTE in the left, right, and both
legs, respectively. In all, 22% presented PE as RVTE as well as
2.0% in the central nervous system. Of all patients, 39% pre-
sented a provoked first thrombosis, and 40% of these patients
had RVTE, corresponding to 16% of all recurrences. This is an
interesting result, since recurrence in patients with a provoked
VTE is expected to be low. Cancer was presented in 13
patients. Three of them had provoked VTE, and only 1 pre-
sented RVTE.
The RVTE events were not in the same location for all
patients. Table 4 shows the relation the VTE/RVTE location
for all patients who presented RVTE. It can be seen that the
thrombotic events repeat more frequently in the same location
for patients who presented VTE in the left leg: Of 24 VTE
patients who presented VTE in the left leg, 16 presented RVTE
in the same location. For other events, this observation is not
the same.
In this study, we used all gathered data to calculate the
eigenvalues and the eigenvectors required to obtain the PCs,
and then using Equation 3, to determine the main factors for
recurrent VTE. Since we considered 39 factors, 39 PCs were
generated. The eigenvalues obtained and the cumulated var-
iance for each PC is shown in Figure 1.
The results indicated that 26 of the 39 PCs correspond to
90.37% of the overall variance. In Figure A, the line y ¼ 1
corresponds to the marginal value below which a PC accounts
for less variance than the original ones. So, only the PCs with
eigenvalues >1 were considered. Thirteen PCs satisfy this con-
dition, so we believe that they are sufficient to describe RVTE,
corresponding to 67.34% of the total variance (horizontal line
in Figure 1B).
Table 2. Codification values for Nonnumerical Variables.
Factor ANN Input Value
Sex Male ¼ 1; Female ¼ 1
Pulmonary embolism Yes ¼ 1; No ¼ 1
Site of thrombosis Right inferior member ¼ 1
Left inferior member ¼ 1
Proximal or distal lower limb thrombosis Proximal ¼ 1; Distal ¼ 1
Provoked or unprovoked Provoked ¼ 1;
Unprovoked ¼ 1
Anticoagulant use Yes ¼ 1; No ¼ 1
FV Leiden Negative ¼ 1;
Heterozygous ¼ 1
G20210A prothrombin gene mutation Negative ¼ 1;
Heterozygous ¼ 1
Antiphospholipid syndrome Negative ¼ 1; Positive ¼
1
Smoking, hormonal therapy, arterial
hypertension, diabetes mellitus,
dyslipidemia, cancer, residual venous
thrombus on US Doppler
Yes ¼ 1; No ¼ 1
Abbreviations: FV, factor V; US, ultrasound.
Table 3. Main Characteristics of the Thrombotic Events.
Time between thrombotic episodes
23.75 + 19.12
months








Left leg 107 23
Right leg 71 15
Pulmonary embolism (exclusive) 42 9
Pulmonary embolism 85 11
Central nervous system 5 1
Both legs 6 1
Abbreviations: RVTE, recurrent venous thromboembolism; VTE, venous
thromboembolism.
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The correlations calculated by Equation 3 between the fac-
tors and the 13 PCs considered are presented in the Supple-
mentary Information (Table S1). A factor can be considered
highly correlated with a PC, therefore an important factor,
when its correlation modulus is higher than 0.5. The correla-
tions for the other PCs (13-39) were not presented, since they
were discarded. The main factors for RVTE found in this work
are presented in Table 5 in order of importance.
Principal component 1 accounted for 13% of overall var-
iance, including red blood cell (RBC) count, hematocrit
(HCT), triglycerides, glucose, creatinine, cholesterol, high-
density lipoprotein (HDL), and low-density lipoprotein
(LDL). The former 3 factors presented much higher correla-
tions with PC1, indicating that they have strong influence in
this PC.
Principal component 2 accounted for 9% of the overall var-
iance, including age, protein C, protein S, and antithrombin
levels. The third component accounted for 8% of the overall
variance, including RBC, hemoglobin (HB), and HCT.
The other highly correlated variables were white blood cell
(WBC) and red cell distribution width (RDW; PC-5: 5.7% of
overall variance), D-dimer (PC-7: 4% of overall variance),
proximal or distal lower limb thrombosis (PC-9: 3.5% of over-
all variance), and duration of anticoagulant treatment (PC-12:
2.92% of overall variance). The other PCs presented no corre-
lation modulus higher then 0.5, indicating that there is no rela-
tive importance between the factors in those PCs.
Discussion
Based on the results, one can relate each PC with a determined
cluster of variables. As we see, PC-1 is characterized by RBC,
Table 4. Relation Between VTE and RVTE Events.
RVTE
VTE Left Leg Right Leg Both Legs Central Nervous System PE Total RVTE
Left leg 16 4 0 2 1 23
Right leg 6 6 1 2 0 15
Both legs 0 0 1 0 0 1
Central nervous system 0 1 0 0 0 1
PE 2 3 1 1 2 9
Total VTE 24 14 3 5 3 49
Abbreviations: PE, pulmonary embolism; RVTE, recurrent venous thromboembolism; VTE, venous thromboembolism.
Figure 1. Principal component analysis (PCA) results. A, Eigenvalues.
B, Cumulated variance.
Table 5. Main Factors for RVTE Determined by PCA.
Principal Components Correlation


















9 Location of VTE in leg 0.657
12 Anticoagulation time 0.522
Abbreviations: HB, hemoglobin; HCT, hematocrit; HDL, high-density lipopro-
tein; LDL, low-density lipoprotein; PC, principal component; PCA, principal
component analysis; RBC, red blood cell; RDW, red blood cell distribution
width; RVTE, recurrent venous thromboembolism; VTE, venous thromboem-
bolism; WBC, white blood cell; AT, Antithrombin; PS, Protein S.
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total cholesterol, LDL and HDL cholesterol, triglycerides, glu-
cose level, and creatinine level. Principal component 2 relates
with age and natural anticoagulants levels. The main factors in
PC-3 are RBC parameters. The size distribution of RBC and
WBC count are the main factors in PC-5. The other PCs pre-
sented only 1 factor as important, so they are mainly character-
ized by them.
It is well-known that the factors for RVTE identified by
PCA in this work are related to thrombotic events3,13,20 as
transient or persistent risk factors such as recent surgery, major
trauma, pregnancy, puerperium, hormone replacement therapy,
and oral contraceptive use and cancer.21 However, since RVTE
is a multifactorial disease, the exact mechanism and interac-
tions between these factors still need a better elucidation.
Principal Component 1
The main factors given by PC-1 corroborate recent publications
regarding the association of RBC, lipids, glucose, and creati-
nine levels with recurrent VTE. From Table S1, one can see
that cholesterol, HDL, and LDL had higher correlation mod-
ulus than the others. This result means that they highly influ-
ence PC-1.
The role of the lipids in VTE is still uncertain, and contra-
dictory results were reported.22,23 It was shown that HDL influ-
ences the extrinsic coagulation pathway, the protein C cascade,
the fibrinolysis, and also reduces blood viscosity. Therefore, it
has antithrombotic properties. On the other hand, triglycerides
have procoagulant effect, suppressing the tissue plasminogen
activator activity and increasing plasminogen activator inhibi-
tor-1.24 A recent prospective study25 showed that there was no
association between these lipid level and recurrent VTE.
Eichinger et al26 reported that lower levels of HDL were asso-
ciated with recurrent VTE. In both studies, blood samples were
collected after 3 months of discontinuation of anticoagulation.
Our results showed that patients with recurrent VTE presented
higher levels of total cholesterol (193.29 + 44.25 mg/dL vs
184.90 + 49.19 mg/dL), HDL (49.29 + 14.91 mg/dL vs 46.41
+ 14.45 mg/dL), and LDL (114.38 + 35.49 mg/dL vs
105.56 + 35.04 mg/dL) than those without recurrence. On the
other hand, the level of triglycerides was lower (148.52 +
60.00 mg/dL vs 156.04 + 152.66 mg/dL). It is important to
mention that when looking at the median, it can be observed
that the values for HDL are 45 mg/mL and 46 mg/mL for
patients with and without RVTE, respectively. Moreover, for
triglycerides, the median is 137 mg/dL and 122 mg/dL
for patients with and without RVTE, respectively. Both results
indicate that the statistical distribution of these factor values is
in agreement with those reported in the literature.
The RBC gained importance in thrombotic events only in
the last decades, when its effects in blood rheology and
endothelium interactions were taken into account as a venous
thrombotic risk factor.27-29 A recent review30 showed that the
RBC influence on recurrent thrombosis can be difficult to inter-
pret but that antithrombotic RBC targets can be developed. Yu
et al31 and Marchioli et al32 stated that high levels of RBC is a
potential risk factor for thrombotic events. Another proposed
mechanism suggest that RBC can interact with the vessel walls,
enhance platelet aggregation and activation, contribute to
thrombin generation, and bind with fibrinogen contributing to
thrombus size.30 Our results showed that patients who pre-
sented recurrent VTE showed higher number of RBC (4.89 
106 + 0.62  106/mL) than those without recurrence (4.61 
106 + 0.62  106/mL), which is in agreement with cited
studies.
Another factor of blood viscosity is the HCT. It was reported
that increase in HCT levels in the venous system can decrease
the blood flow due to the increase in its viscosity, thus favoring
clot formation,33,34 platelet adhesion, and accumulation at the
subendothelial cells.30 Indeed, higher HCT levels were previ-
ously correlated with thrombotic events.20 As far as we know,
there is only 1 study that reported HCT level as a predictor of
recurrent VTE. The study of Eischer et al35 showed that
patients with RVTE presented higher HCT levels (3 months
after discontinuation of anticoagulation) than those without
recurrence. However, higher levels of HCT correlated with
recurrent VTE in women and not in men. Our results showed
that HCT level in patients with RVTE were higher (42.16% +
4.39%) than those without (40.70% + 4.95%).
The role of glucose level in RVTE is still uncertain and as
far as we know, there are no studies that analyzed its effects on
it. High glucose levels can trigger the coagulation system in
healthy men and in patients with diabetes mellitus.36,37 For this
reason, we choose to include this factor in the study. Our results
demonstrated that patients with RVTE presented lower glucose
levels than those without recurrent episodes (93.12 + 21.27
mg/dL vs 105.23 + 51.17 mg/dL, respectively). Besides, this
is not an expected result, recurrence is multifactorial, and the
interaction with other factors could influence the thrombus
formation.
The role of creatinine level on RVTE is still unknown. Shli-
pak et al38 reported that higher creatinine levels are accompa-
nied with the increase in factor VII, factor VIII, and D-dimer,
which can lead to VTE events. Our results showed that patients
with higher levels of creatinine have RVTE episodes against
those with lower creatinine levels (0.86 + 0.23 mg/dL vs 0.83
+ 0.31 mg/dL).
Principal Component 2
Age and coagulation proteins are the main identifiers of PC-2,
and, as shown Table S1, their importance on the PC is similar.
Age is a well-known important factor for thrombosis. Several
research indicated that the thrombosis affects 0.01% of the
population before the age of 40, and 0.7% of the population
between the ages 45 and 55. In addition, the morbidity is higher
as age increases.4,39,40 Hansson et al13 and Farzamnia et al3
showed that age has no direct relation between age and a higher
risk of recurrence. White et al41 reported that recurrence was
more common in younger patients, while Beyth et al42 found
that this was observed in patients aged 65 and younger. On the
other hand, Heit et al,2 Eichinger et al,26 and Galanaud et al,43
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reported that increasing age was related to a higher risk of
recurrence. Our results showed that patients with RVTE pre-
sented similar average age (43.40 + 14.82 years) against
(44.05 + 16.07 years) those without recurrence.
Deficiency of natural anticoagulants can trigger hypercoa-
gulability and a thrombotic event.36,44-47 Rosendaal and
Reitsma47 reported that these deficiencies are a strong risk
factor for VTE. However, the authors affirm that this is not
necessarily true for RVTE. De Stefano et al48 indicated that
patients with these deficiencies have an increased risk of recur-
rent VTE. Our results showed that antithrombin, protein C, and
protein S activity were important factors, as patients with
RVTE presented lower levels of these proteins when compared
to those without recurrence (Protein C: 106.26 + 28.39
mgdL1; Protein S: 90.69 + 23.83 mgdL1; antithrombin:
105.69 + 16.11 mgdL1 vs Protein C: 117.87 + 23.60
mgdL1; Protein S: 92.41 + 23.44 mgdL1; antithrombin:
106.22 + 15.57 mgdL1, respectively). These results are very
interesting as even without a classical deficiency, we showed
that lower levels are important for RVTE. Our findings are in
agreement Xu et al49 who proposed a mathematical model for
the coagulation cascade and showed that lower levels of protein
C is associated with thrombus formation.
Principal Component 3
Principal component 3 is characterized by the RBC parameters:
RBC, HB, and HCT. Both RBC and HCT were also important
factors in PC-1. Since each PC is calculated as a function of all
original factors, one factor can be important in more than one
PC due the multidimensionality of the problem. However, their
importance in PC-3 is higher. As we previously discussed,
RBC and HCT can be associated with VTE and RVTE. Bræk-
kan et al20 found a direct relation between HB at the admission
and VTE: The higher the HB levels, the higher the risk of VTE.
Our results showed that patients with recurrence presented
similar levels of HB (13.99 + 1.44 g/dL) when compared to
those without (13.54 + 1.77 g/dL). As far as we know, there is
no study that evaluated the influence of HB levels in RVTE.
However, it is known that HB molecules released from dam-
aged RBCs enhance platelet activation and aggregation.30
Principal Component 5
Both RDW and WBC are the major descriptors of PC-5.
The leukocyte number and the RDW have been related to
thrombotic events.50-52 However, their role in RVTE is still
not well established. Some studies showed that high WBC
count is related to RVTE.53-55 On the other hand, the study
of Rezende et al56 reported that those with higher risk of
VTE presented lower levels of WBC and higher levels of
RDW after VTE. The authors also suggested that other
studies should be performed to investigate the relationship
between these variables with RVTE. Our results showed
that patients with VTE recurrence presented lower levels
of WBC (6.89.103 + 2.69.103/mL) and higher levels of
RDW (14.17 + 1.96%) than those without recurrence
(WBC: 7.94.103 + 3.86.103/mL; RDW: 13.59 + 1.49%).
Remaining PCs
D-Dimer, proximal or distal lower limb thrombosis, and dura-
tion of anticoagulant treatment are the descriptors of PC-7,
PC-9, and PC-12, respectively. D-Dimer is the most important
predictor factor for VTE and its recurrence, and several studies
about its influence can be found in the literature.57-60 Eichinger
et al61 and Palareti et al62 found that there is an association of
high level of D-dimer and high recurrence risk. Also, in a recent
study, Bjøri et al63 reported that those with D-dimer level <1500
ngmL1 at diagnosis were associated with a low recurrence
risk. Our results showed that D-dimer level in patients with
recurrence are in agreement with all the studies cited (with
RVTE: 839.13 + 1101.97 ngmL1; without RVTE: 672.68
+ 981.58 ngmL1).
According to Galanaud et al,43 the influence of the location
of VTE on the leg for RVTE is important. The authors con-
cluded that those with proximal VTE presented more recurrent
thrombotic events than those with distal VTE. Boutitie et al64
and Hansson et al13 reported similar results. Our results showed
that 83% of patients with distal VTE presented recurrence
against 16% of those with proximal VTE.
Time of anticoagulation therapy is one of the major factors
that can lead or prevent RVTE.65 This is a subject of debate,
and its recommendations can be found in the American College
of Chest Physicians Guidelines.66 Boutitie et al64 reported that
patients treated for 6 months or more presented lower RVTE
events than those treated during 3 months. Also, that patients
treated for 1 or 1.5 months presented higher risk of RVTE than
those treated for 3 months. In a recent study, Agnelli et al11
evaluated the extended anticoagulation therapy with apixaban
and reported that the extended therapy reduced the risk of
recurrence without increasing the risk of bleeding. Similar
results are reported in Investigators.12 Studies that analyze the
time of anticoagulant after a first recurrence can also be found
in the literature.67,68 Our results showed that patients with
RVTE were treated during a longer time than those without
recurrence (12.72 + 18.51 months vs 9.88 + 11.50 months).
This result was somewhat unexpected, since patients with less
time of anticoagulation therapy is supposed to have higher
probability of RVTE. However, when comparing only patients
with RVTE (data not shown), it could be observed that RVTE
occurred mainly in patients treated during shorter periods.
The results obtained in this work showed that RVTE, a
priori, can be predicted using clinical parameters and data from
the previous thrombosis. It is important to mention that some
variables were expected to be within the main factors, but they
were not indicated by PCA, since only variables with correla-
tion above 0.500 usually are considered as important.
The first one is the provoked/unprovoked VTE factor. Our
results showed that 16% of all patients with RVTE had a first
provoked VTE. On a daily basis, patients with provoked VTE
are usually treated during 3 to 6 months, and then the
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anticoagulation therapy is ceased. However, a different deci-
sion could avoid such a high recurrence rate. This factor is
reported in Supplementary Table S1 with a correlation of
0.493 in PC-4, which is very close to 0.500. Due to its impor-
tance to RVTE, this factor could be included as input in a
prediction model. Cancer is another variable expected to be
in the main factors list. However, only 13 patients of 235 pre-
sented this disease. Therefore, its influence is too small when
compared to the other 38 variables. This can be confirmed by
its correlation coefficients in Supplementary Table S1, which
are smaller than 0.360. A future study should address only
these patients.
Main Limitations
The limitations for this study are mainly due the sample size,
which is small considering the eligible population. However,
for determination of the main factors using PCA, it was con-
sidered to be sufficient. The results showed that the important
predictors of RVTE are in agreement with previous studies and
are simple to obtain in clinical routine. Future work should
consider another population for validation purposes.
Conclusion
In this work, PCA was applied in order to identify the main
factors that predict recurrent deep vein thrombosis. Our results
showed that 13 PCs are sufficient to describe the phenomenon
and that 18 of 39 factors are the important for RVTE analysis.
The important factors include blood cells, lipids, coagulation
proteins levels, renal disease, age, as well as previous VTE
parameters. This work showed that simple parameters,
obtained directly from blood measurements, could be used to
develop a model to predict the rates of RVTE.
Authors’ Note
Each author contributed to the development of the manuscript,
reviewed, and commented on each draft, and approved the final draft.
R. Maciel-Filho and J. M. Annichino-Bizzacchi contributed to the
study protocol. J. M. Annichino-Bizzacchi and A.V.C. Romano con-
tributed to data acquisition. T. D. Martins and R. Maciel-Filho con-
tributed to study design. T. D. Martins, J. M. Annichino-Bizzacchi,
A.V.C. Romano, and R. Maciel-Filho contributed to data interpreta-
tion and discussion. Ethical approval to report this case was obtained
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